Saleem P, Olié J P, Loo H
Department of Psychiatry, Queen's Park Hospital, Blackburn, UK.
Int Clin Psychopharmacol. 2002 Jan;17(1):1-8. doi: 10.1097/00004850-200201000-00001.
Schizophrenia is associated with significant social, psychological and occupational dysfunction. Not only is this distressing for the patients and their family and friends, but it also results in high indirect costs. Reintegration back into society, one of the most important aspects of quality life for schizophrenic patients and their physicians, must therefore take into account a patient's social functioning and employability, as well as improvement in symptoms. Although the typical antipsychotics are effective in managing the positive symptoms of schizophrenia, they may not alleviate other aspects of the disorder. They are also associated with extrapyramidal symptoms and other severe adverse events that have significant consequences for quality of life and compliance. The atypical antipsychotic, amisulpride, has an improved safety and tolerability profile and has been shown to be significantly more effective than placebo and haloperidol on a number of quality of life and social functioning scales, including the Global Assessment of Functioning, the Quality of Life Scale, the Functional Status Questionnaire and the Psychosocial Aptitude Rating Scale. In conclusion, amisulpride, in addition to its proven clinical efficacy, may help reintegration of the schizophrenic patient back into society.
精神分裂症与严重的社会、心理和职业功能障碍相关。这不仅给患者及其家人和朋友带来痛苦,还导致高昂的间接成本。因此,重新融入社会作为精神分裂症患者及其医生生活质量的最重要方面之一,必须考虑患者的社会功能和就业能力,以及症状的改善。尽管典型抗精神病药物在控制精神分裂症的阳性症状方面有效,但它们可能无法缓解该疾病的其他方面。它们还与锥体外系症状和其他严重不良事件相关,这些对生活质量和依从性有重大影响。非典型抗精神病药物氨磺必利具有更好的安全性和耐受性,并且在一些生活质量和社会功能量表上,包括功能总体评定量表、生活质量量表、功能状态问卷和社会心理能力评定量表,已被证明比安慰剂和氟哌啶醇显著更有效。总之,氨磺必利除了已证实的临床疗效外,可能有助于精神分裂症患者重新融入社会。